We are live on ! Find out more
AEGR

Aegerion Pharmaceuticals
AEGR

Delisted

AEGR was delisted on the 29th of November, 2016.

Back to rankings

0 hedge funds and large institutions have $0 invested in Aegerion Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 58 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 58 → 0 (-58)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $84.5M → $0 (-$84.5M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 58

Holders
–
Holders Change
-58
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
58
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SCM
Scopia Capital Management
New York
-$16.9M
2
BC
Broadfin Capital
New York
-$13M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$8.52M
4
SCM
Sarissa Capital Management
Connecticut
-$7.87M
5
Renaissance Technologies
Renaissance Technologies
New York
-$5.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Scopia Capital Management
New York
– -$16.9M -5,703,587 Closed
BC
2
Broadfin Capital
New York
– -$13M -4,361,291 Closed
Fidelity Investments
3
Fidelity Investments
Massachusetts
– -$8.52M -2,867,572 Closed
SCM
4
Sarissa Capital Management
Connecticut
– -$7.87M -2,649,000 Closed
Renaissance Technologies
5
Renaissance Technologies
New York
– -$5.1M -1,716,200 Closed
AC
6
Armistice Capital
New York
– -$3.84M -1,292,000 Closed
Vanguard Group
7
Vanguard Group
Pennsylvania
– -$3.32M -1,117,826 Closed
AG
8
Artal Group
Luxembourg
– -$2.97M -1,000,000 Closed
JG
9
Jefferies Group
New York
– -$2.12M -712,948 Closed
BIT
10
BlackRock Institutional Trust
California
– -$1.78M -600,132 Closed
BFA
11
BlackRock Fund Advisors
California
– -$1.44M -484,936 Closed
SIM
12
Spark Investment Management
New York
– -$925K -311,600 Closed
Two Sigma Investments
13
Two Sigma Investments
New York
– -$726K -244,386 Closed
Goldman Sachs
14
Goldman Sachs
New York
– -$649K -218,481 Closed
Geode Capital Management
15
Geode Capital Management
Massachusetts
– -$496K -167,216 Closed
Millennium Management
16
Millennium Management
New York
– -$493K -165,879 Closed
CS
17
Credit Suisse
Switzerland
– -$477K -160,294 Closed
KPF
18
K2 Principal Fund
Ontario, Canada
– -$370K -124,454 Closed
Federated Hermes
19
Federated Hermes
Pennsylvania
– -$328K -110,280 Closed
Connor, Clark & Lunn Investment Management (CC&L)
20
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
– -$316K -106,500 Closed
Northern Trust
21
Northern Trust
Illinois
– -$269K -90,346 Closed
FIM
22
Freedom Investment Management
Connecticut
– -$251K -84,632 Closed
T. Rowe Price Associates
23
T. Rowe Price Associates
Maryland
– -$242K -81,600 Closed
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
– -$228K -76,709 Closed
AA
25
Ancora Advisors
Ohio
– -$217K -73,212 Closed
1
2 3

AEGR Hedge Fund Activity: Q4 2016 in Review

0 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Aegerion Pharmaceuticals (AEGR) for Q4 2016, worth a combined $0 — down 100% from $84.5M a quarter earlier.

Sellers outnumbered buyers: 58 funds closed out of AEGR and 0 opened new positions — a net loss of 58 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Scopia Capital Management, exiting entirely with an estimated $16.9M sold.

  • 0 institutional investors held Aegerion Pharmaceuticals (AEGR) as of Q4 2016, down from 58 in Q3 2016.
  • Funds reported $0 of Aegerion Pharmaceuticals stock for Q4 2016, down 100% quarter-over-quarter.
  • 0 funds opened new Aegerion Pharmaceuticals positions in Q4 2016 and 58 closed out, a net change of -58 holders.
  • The largest Aegerion Pharmaceuticals seller in Q4 2016 was Scopia Capital Management, an estimated $16.9M sold.

Based on aggregated 13F filings for Q4 2016.